# Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

> **NCT00454909** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 873 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Meningococcal vaccine 134612
- **BIOLOGICAL:** Menactra®

## Key facts

- **NCT ID:** NCT00454909
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-23
- **Primary completion:** 2007-10-31
- **Final completion:** 2008-04-11
- **Target enrollment:** 873 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454909, "Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00454909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*